(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual revenue growth rate of -29.88% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Aclaris Therapeutics's revenue in 2024 is $31,249,000.On average, 6 Wall Street analysts forecast ACRS's revenue for 2024 to be $535,767,767, with the lowest ACRS revenue forecast at $160,290,595, and the highest ACRS revenue forecast at $1,517,795,899. On average, 5 Wall Street analysts forecast ACRS's revenue for 2025 to be $638,609,078, with the lowest ACRS revenue forecast at $160,290,595, and the highest ACRS revenue forecast at $1,666,738,487.
In 2026, ACRS is forecast to generate $772,090,007 in revenue, with the lowest revenue forecast at $160,290,595 and the highest revenue forecast at $1,836,958,588.